Ac-PHSCN-NH2 | Raf signal

Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting a5b1 integrin

Hongren Yao

Donna M. Veine

Donna L. Livant

⦁ eceived: 24 March 2016 / Accepted: 24 May 2016
⦁ pringer Science+Business Media New York 2016

Abstract At diagnosis, 10 % of breast cancer patients already have locally advanced or metastatic disease; more- over, metastasis eventually develops in at least 40 % of early breast cancer patients. Osteolytic bone colonization occurs in 80–85 % of metastatic breast cancer patients and is thought to be an early step in metastatic progression. Thus, breast cancer displays a strong preference for metastasis to bone, and most metastatic breast cancer patients will experience its complications. Our prior research has shown that the a5b1 integrin ﬁbronectin receptor mediates both metastatic and angiogenic invasion. We invented a targeted peptide inhibitor

kg PhScN monotherapy reduces established intratibial MDA- MB-231 bone colony progression by 80 %. Thus, PhScN is a highly potent, well-tolerated inhibitor of both lung colo- nization and bone colony progression.

Keywords Breast cancer Invasion Bone metastasis Extravasation Lung metastasis Integrin ﬁbronectin receptor Systemic therapy

Abbreviations
SF Serum free

of activated a5b1, Ac-PHSCN-NH2
(PHSCN), as a validated
FBS Fetal bovine serum

lead compound to impede both metastatic invasion and neovascularization. Systemic PHSCN monotherapy pre- vented disease progression for up to 14 months in Phase I clinical trial. Here, we report that the next-generation con- struct, Ac-PhScN-NH2 (PhScN), which contains D-isomers of histidine (h) and cysteine (c), is greater than 100,000-fold more potent than PHSCN at blocking basement membrane invasion. Moreover, PhScN is also up to 10,000-fold more potent than PHSCN at inhibiting lung extravasation and colonization in athymic mice for both MDA-MB-231 meta- static and SUM149PT inﬂammatory breast cancer cells. Furthermore, we show that systemic treatment with 50 mg/

& Donna L. Livant
Bio Biotin
IC50 Concentration for 50 % inhibition
pFn Plasma ﬁbronectin
DRI Dose reduction index
DiI 1,1 -Dilinoleyl-3,3,3 3 – tetramethylindocarbocyanine perchlorate
MAP Multiantigenic peptide
MAb Monoclonal antibody
SEM Standard error of mean
Me Methyl
OAc Acetyl
lg Microgram
ng Nanogram
pg Picogram
mw Molecular weight

[email protected]
Hongren Yao
[email protected]
Kd
Dissociation constant

1
Donna M. Veine
[email protected]

Department of Radiation Oncology and Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5637, USA
Background

Metastatic disease develops in 40 % of early breast cancer patients [1] and rapidly metastasizes to bone in 85 % [2, 3]. Bone metastases are osteolytic [2], releasing factors from

123

0 0 0
nu

the matrix stimulating tumor growth and bone resorption: the ‘‘vicious cycle’’[2]. Because inﬂammatory breast cancer (IBC) patients have lymph node involvement and distant metastases at diagnosis, IBC is similar to metastatic breast cancer [1].
Interaction of activated a5b1 integrin ﬁbronectin receptors of metastatic or inﬂammatory breast cancer cells with the plasma ﬁbronectin (pFn) PHSRN sequence indu- ces constitutive invasion [4]. Moreover, a5b1 regulates invasion [5], angiogenesis [6], extravasation, and colo- nization by breast and other adenocarcinomas [7–13].
Breast Cancer Res Treat

In vitro invasion assays

In vitro invasion assays employing naturally serum-free (SF) basement membranes (SU-ECM) were performed and data analyzed as in [4–9, 14, 16, 17]. Peptides were pre- bound to serum-starved, suspended cells prior to placement on SU-ECM. Mean invasion percentages were analyzed using Prism software (GraphPad Software, San Diego, CA) as a function of log (inhibitor) versus normalized data, variable slope.

Radiation stimulates invasion by inducing surface upreg-
Determination of dissociation, K
d
, and inhibition

ulation of activated a5b1 integrin [14].
We devised a potent, targeted a5b1 integrin inhibitor,
constants, Ki
, for cell surface binding

Ac-PHSCN-NH
2
(PHSCN), as a validated lead compound
PHSCN and PhScN dissociation constants were determined

to prevent metastatic [5] and angiogenic invasion [6]. In Phase I clinical trial, systemic PHSCN monotherapy pre- vented disease progression for up to 14 months [15]. Here, we report that Ac-PhScN-NH2—containing D-isomers of histidine (h) and cysteine (c)—is over 100,000-fold more potent than PHSCN at blocking basement membrane invasion by MDA-MB-231 and SUM149PT breast cancer
by centrifugation binding assays [18], using biotinylated, N-acetylated, C-amidated Ac-PHSCNGGK-Bio and Ac- PhScNGGK-Bio [9, 12]. Maximal a5b1 activation was promoted by manganese. Binding experiments were per- formed as pairs to ensure consistency. 150,000 cells, sus- pended in binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.1 % bovine calf serum, and 2 mM

cells. We also report that PhScN is 100- to 10,000-fold
MnCl
2
) were incubated with varying concentrations of

more potent at inhibiting lung extravasation, and 1000- to 10,000-fold more potent at reducing lung colonization in nude mice. Finally, we report that systemic 50 mg/kg PhScN monotherapy reduces established MDA-MB-231 intratibial colony progression by almost 80 %. Thus, PhScN is a highly potent, well-tolerated inhibitor of bone colony progression.

Materials and methods

Cell lines and cell culture

SUM149PT (Asterand USA, Detroit, MI), MDA-MB-231, and human microvascular endothelial cells (American Type Culture Collection, Manassas, VA) were cultured as recommended, and microscopic morphologies were rou- tinely checked.

Peptide synthesis

N-terminal-acetylated, C-terminal-amidated PhScN, PHSCN, hSPNc, and HSPNC peptides, PhScNGGK-MAP poly-lysine dendrimer, and cysteine or biotinylated (-Bio) derivatives were synthesized and puriﬁed to 95 % by Peptide 2.0 (Chantilly, VA), Peptisyntha, Inc. (Torrance, CA) or the University of Michigan Peptide Synthesis Core.

123
biotinylated peptides for 2 h at 4 C. Washed cell pellets were incubated at 4 C for 30 min with Streptavidin-per- oxidase (Sigma) and o-phenylenediamine substrate, stabi- lized by the addition of HCl. Absorbances were recorded at 490 nM.
Competition assays were performed with a constant concentration of biotinylated peptide and varying amounts of unlabeled competitor. Equilibrium time was 3 h [9]. Binding data were analyzed, and curves were ﬁt using nonlinear regression approaches [9, 19].

Fluorescent DiI labeling of MDA-MB-231
and SUM149PT cells

Washed, conﬂuent cells were suspended and orange ﬂuo- rescently labeled in SF medium with lipophilic carbocya- nine vital dye DiI, 1,1 -dilinoleyl-3,3,3 3 -tetramethylindo- carbocyanine perchlorate (Invitrogen) [7–9]. Labeled cells were pelleted, resuspended in 6 ml of medium, and cul- tured 72 h prior to use.

Mice

Female Foxn1 athymic nude mice (Harlan) were housed according to the Association for the Assessment and Accreditation for Laboratory Animal Care guidelines. Studies were performed with approved institutional animal use protocols.

Breast Cancer Res Treat

Lung extravasation and colonization by MDA-MB- 231 or SUM149PT cells

Extravasation-inhibitory potencies of single systemic pre-

actin [7–9]. Twenty 10-micron sections, separated by 200 microns, were analyzed from each tibia.

Data analysis

treatments of Ac-PhScN-NH2
, Ac-PHSCN-NH2, or Ac-

PhScNGGK-MAP were evaluated using DiI-labeled, pep- tide- or dendrimer-prebound cells [7–9]. Treated cells were
Dose response data were analyzed as in [9] by Chou– Talalay Combination index (CI) [21], based on the multiple

prebound with 1, 10, or 100 ng/ml Ac-PhScN-NH
2
; 10,
drug effect equation, where y = log(fa/fu), with respect to

100, or 1000 ng/ml Ac-PHSCN-NH2; 1000 ng/ml Ac- HSPNC-NH2; or 1000 ng/ml Ac-hSPNc-NH2, for 10 min at 37 C. Groups of 10 nude mice received one systemic pretreatment with the appropriate peptide concentration by
x = log(dose), deﬁnes the dose effect relationship without reaction rate constants. fa is the fraction of cells affected (invasion-inhibited), and fu is the fraction of cells unaf- fected (invaded). The x intercept represents the IC50 value.

tail vein injection. Immediately thereafter, 10,000 cells,
CI and DRI values were determined for Ac-PhScN-NH
2
,

prebound with the appropriate peptide or with HBSS only
relative to Ac-PHSCN-NH
2
.

were injected into tail veins in 0.1 ml HBSS. Mice received no other systemic treatments were euthanized 24 h later, and their lungs were removed. Frozen-tissue samples were prepared, and lung-extravasated cells were quantitated at 400-fold magniﬁcation by Zeiss Scanning Laser Confocal microscopy (LSM510). 25 10-lm sections, taken at inter- vals of 100 lm, were analyzed from one lung in each mouse. Data are presented as mean ± SEM. Mice evalu- ated for lung colonization were maintained without further treatment for 6 weeks prior to euthanization.

Results

Increased invasion-inhibitory potency of Ac-PhScN- NH2, and Ac-PhScNGGK-MAP

SF SU-ECM basement membranes [9] were utilized to evaluate invasion-inhibitory potencies of S-acetylated or S-methylated PHSCN derivatives [Ac-PHSC(S-OAc)N-

NH
2
and Ac-PHSC(S-Me)N-NH
2
], the D-His, D-Cys-

Western blot analysis of activated caspase-3
in SUM149PT cells

Adherent SUM149PT cells were serum-starved overnight, then incubated in serum-containing medium with 0, 10, 50,
containing PhScN peptide (Ac-PhScN-NH2), and the D-His, D-Cys-containing PhScNGGK poly-lysine multi- antigenic peptide dendrimer (Ac-PhScNGGK-MAP) on a5b1-mediated, serum-induced, or SF PHSRN-induced invasion. Figure 1a shows Hill-Slope plots evaluating

100, 200, or 300 lg of Ac-PhScN-NH
2
, or 500 lg per 10
6
effects of varying concentrations of Ac-PHSC(S-OAc)N-

cells of Ac-hSPNc-NH2
for 1 h, prior to washing thrice
NH
2
, Ac-PHSC(S-Me)N-NH2
, and Ac-PhScN-NH
2
on

with PBS. Anti-cleaved Caspase 3 MAb (Cell Signaling
FCS-induced invasion, compared to Ac-PHSCN-NH
2

#9661) primary antibody and horseradish peroxidase HRP- linked anti-rabbit IgG (Cell Signaling, #7074) were used in Western blot analysis of cleaved Caspase-3, as instructed.

Intratibial injection of DiI-labeled MDA-MB-231
(Fig. 1a). To demonstrate that PhScN targets a5b1 inte- grin-mediated invasion, the a5b1-speci ﬁc Fn cell-binding domain ligand [22], Ac-PHSRN-NH2 (PHSRN), was used to induce SF invasion by MDA-MB-231 (Fig. 1b). The alternating L- and D-stereoisomer sequence of Ac-PhScN-

cells
NH
2
produced an endoproteinase-resistant peptide with a

Treatment groups of 10 mice were each injected in right tibial crest cortex with 10,000 DiI-labeled MDA-MB-231 cells, not pretreated with peptide [20]. Intratibial colonies progressed untreated for 2 weeks prior to initiation of thrice-weekly PhScN or PHSCN therapies, at 0.0, 5.0, and 50.0 mg/kg. Sterile peptide solutions were prepared in 50 mM HEPES, pH 7.4, and tail vein injected in 100 ll. Mice were euthanized 24 days later, after 10 systemic
100,000-fold increased invasion-inhibitory potency, for serum-induced and SF PHSRN-induced invasion, similar to that achieved by covalent S-modiﬁcation of the PHSCN cysteine residue. Similar Hill-Slope plots were obtained for SUM149PT (Table 1).
Table 1 summarizes half maximal invasion-inhibitory concentration (IC50) and dose reduction index (DRI) values for PHSCN and S-methylated [C(Me)N] or S-acetylated [C(OAc)N] derivatives for MDA-MB-231 and

treatments. Tibia were ﬁxed in 4.0 % paraformaldehyde at
SUM149PT. IC
50
and DRI values based on pg/ml or molar

4 C for 3 days, rinsed in 1.0 % PBS for 2 days, and then
(M) concentrations are presented for Ac-PhScN-NH
2

stored in 20.0 % sucrose until transfer to a sucrose series in mounting medium, followed by embedding and staining with DAPI, conjugated with green ﬂuorescence-labeled
(PhScN) and Ac-PhScNGGK-MAP dendrimer (cN-MAP) for serum- or SF Ac-PHSRN-NH2 (PHSRN)-induced invasion. Since PhScN is a highly potent inhibitor of SF

123

% Relative Invasion
% Relative Invasion
7
2
4
6
5
-8
-8
11 12
12 13

Breast Cancer Res Treat

120
100
80
60
40
20

PHSCN
PhScN
PHSC(ME)N
PHSC(O-Ac)N

PHSRN-induced invasion by MDA-MB-231 and SUM149PT, PhScN targets a5b1-mediated invasion in both cell lines.
PHSCN was suggested to inhibit invasion via disulﬁde bonding with a5b1 integrin [10]. However, increased-in- hibitory potencies of the S-acetylated or S-methylated PHSCN derivatives for MDA MB231 and SUM149PT cells, and for prostate cancer [9], suggest that the produc-

-4 -2 0 2 4 6 8
log(pg/ml)
tive mechanism is noncovalent.
PhScNGGK-MAP (7500 Da), containing 8 subunits of PhScN demonstrated a 10 -fold increased invasion-in-

PhScN

120
hibitory potency over monomeric PhScN (596 Da), sig- niﬁcantly greater than the 1000-fold increase seen when

100
CN-MAP
comparing PHSCNGGK-MAP and PHSCN [7, 8] (Fig. 1b;

cN-MAP
80
60
40
20
PHSCN
Table 1).

Dissociation constants (Kd) and competition binding assays for cell surface binding using biotinylated PhScN or PHSCN

-8 -6 -4 -2 0 2 4 6 8
log(pg/ml)

Fig. 1 Hill-slope plots of increased invasion-inhibitory potency of Ac-PhScN-NH2 peptide, Ac-PhScNGGK-MAP dendrimer, and the cysteine-modiﬁed, methylated (Me), or acetylated (OAc) peptides,

D-amino acid substitutions change the orientation of the side chains on the PhScN peptide backbone, which could affect target binding and explain the 100,000-fold increase in PhScN invasion-inhibitory potency. A binding assay, developed to determine the dissociation constant (Kd) of

Ac-PHSC(Me)N-NH
2, and Ac-PHSC(OAc)N-NH
2
for MDA-MB-231
biotin-labeled PHSCN peptide to suspended cells [10], was

cells. a Effects on FBS-induced invasion by cysteine-modiﬁed Ac- PHSC(Me)N-NH2 or Ac-PHSC(OAc)N-NH2, and D-His, D-Cys containing Ac-PhScN-NH2 peptides. Symbols are denoted in the ﬁgure. X axis, log peptide concentration in pg per ml; Y axis, mean
utilized to compare the Kd’s of biotinylated PhScN and PHSCN peptides. The invasion-inhibitory potencies of biotinylated PHSCN and PhScN were conﬁrmed on SU-

relative percentages of invaded cells (±SD). IC50 and DRI values are
ECM. IC
50
’s of Ac-PhScNGGK-Bio and Ac-PHSCNGGK-

summarized in Table 1. b Increased potencies of PhScN peptide and PhScN dendrimer for both serum-induced and serum-free (SF), Ac- PHSRN-NH2 (1 lg/ml)-induced, a5b1-mediated invasion. Circles denote Ac-PhScN-NH 2; squares denote Ac-PhScNGGK-MAP den-
Bio were similar to those of Ac-PhScN-NH2 and Ac- PHSCN-NH2, respectively, for suspended MDA-MB-231 (Fig. 2a; Table 2) and SUM149PT (Table 2).

drimer; and triangles denote Ac-hSPNc-NH
2. Closed symbols denote
As shown in Fig. 2b and summarized in Table 2, Kd’s for

FBS-induced and open symbols denote Ac-PHSRN-NH2 (1 lg/ml) induced, SF invasion. X axis, log peptide concentration in pg/ml; Y axis, mean relative percentage of invaded cells (±SD). The solid and dashed lines represent published values for Ac-PHSCN-NH2 and Ac-PHSCNGGK-MAP, respectively [7]
Ac-PHSCNGGK-Bio binding to suspended SUM149PT and MDA-MB-231 cells were 0.028 and 0.032 lM, respectively. Kd values for Ac-PhScNGGK-Bio were 0.029 and 0.053 lM for suspended SUM 149PT and MDA-MB-

Table 1 Inhibition of a5b1- mediated invasion of basement

Mw SUM149 PT MDA-MB-231 DRI

membranes by SUM149PT and
IC
50
IC50

MDA-Mb-231 cells: IC50 and DRI values for PhScN and PHSCN derivatives
FBS PHSRN FBS PHSRN
pg/ml pg/ml pg/ml pg/ml pg/ml M
PHSCN 598 8980 67,120 16,800 14,500 1
1
CN-MAP 7500 125 152 128 90 10
10

C(Me)N 614 0.27
–
0.36 –
10
10
4

C(OAc)N 640 0.01
–
0.01
–
10
10
6

PhScN 598 0.076
0.081
0.135 0.124
10
10
5

cN-MAP 7500 4.4 9 10
7.6 9 10
1.3 9 10
-7
1.1 9 10
-7
10 –10
10 –10

123

Breast Cancer Res Treat

231, respectively. Since PhScN and PHSCN Kd values were similar, the improved invasion-inhibitory potency of PhScN (Table 1) is due to elimination of the nonproductive cova- lent side reaction by orienting the D-His and D-Cys side chains to the opposite side of the peptide ligand, rather than to tighter binding, as for prostate cancer [9]. Thus, nonco- valent interaction is key to invasion-inhibitory potency.
Competition assays were also performed to conﬁrm that PHSCN and PhScN interact with the same binding site on breast cancer cells, like prostate cancer [9]. Results of assays, in which suspended MDA-MB-231 cells were incubated with a constant concentration (0.1 lM) of biotinylated Ac-PHSCNGGK-Bio and varying concentra-

tions of Ac-PhScN-NH
2
, are presented in Fig. 2c. They

show that dissociation of Ac-PHSCNGGK-Bio with

increasing concentrations of unlabeled Ac-PhScN-NH
2

occurs over 2 orders of magnitude, demonstrating that PhScN and PHSCN compete for the same binding site on MDA-MB-231 [19], as for SUM149PT, not shown.

Increased lung extravasation inhibition by PhScN and PhScNGGK-MAP

Lung extravasation-inhibitory efﬁcacies of PhScN and PhScNGGK-MAP were compared with PHSCN in nude mice. As shown in Fig. 3a, the mean number of extra- vasated MDA-MB-231 and SUM149PT cells per section was decreased by 100- to 1000-fold by Ac-PhScN-NH2, and by at least 100,000-fold by Ac-PhScNGGK-MAP,

relative to Ac-PHSCN-NH2
. The median-effect plot of

Fig. 2 a Hill-slope plots of invasion inhibition by biotinylated derivatives of PHSCN and PhScN for MDA-MB-231 cells induced by FBS. Speci ﬁc agents (CN-Bio, Ac-PHSCNGGK-Bio; cN-Bio, Ac- PhScNGGK-Bio) are listed on the right. X axis, log peptide concentration in pg per ml; Y axis, mean relative percentages of invaded cells (±SD). IC50 and DRI values are summarized in Table 2. b Kd binding assays for Ac-PHSCNGGK-Bio (CN-Bio) and Ac- PhScNGGK-Bio (cN-Bio) peptides with suspended MDA MB231
Fig. 3b shows that increasing concentrations of PhScN or PHSCN, or PhScNGGK-MAP dendrimer, log-linearly decrease SUM149PT and MDA-MB-231 extravasation, with similar relative potencies. Pretreatment with 1 lg per ml Ac-hSPNc-NH2 scrambled sequence control, followed by a single systemic treatment at the equivalent dose, had no inhibitory effect on extravasation, not shown. As sum- marized in Table 3, Ac-PhScN-NH2 is 100- to 1000-fold

cells. Plots were ﬁt using a total binding equation to account for
more potent than Ac-PHSCN-NH
2
at inhibiting

nonspeciﬁc binding [19]. c Competition binding was determined by incubating suspended MDA-MB-231 cells with a constant concen- tration of 0.1 lM Ac-PHSCNGGK-Bio (labeled) and varying amounts of unlabeled Ac-PhScN-NH2. Plot was ﬁtted using the Motulsky and Neubig competitive inhibition equation [19]
SUM149PT and MDA-MB-231 lung extravasation, and Ac-PhScNGGK-MAP is 100,000- to 1000,000-fold more potent. These in vivo values correlate with those seen in SU-ECM invasion assays (Table 1), and are similar to

Table 2 Invasion inhibition: IC50 and Kd ‘s for biotinylated PhScN and PHSCN derivatives

Mw SUM149 PT MDA-MB-231
IC50 (pg/ml) Kd (lM) IC50 (pg/ml) Kd (lM)

Ac-PHSCN-NH

2
598 8980 NA 16,800 NA

Ac-PhScN-NH
2
598 0.076 NA 0.124 NA

Ac-PHSCNGGK-Bio 1100 8637 0.028 ± 0.02 5622 0.032 ± 0.03 Ac-PhScNGGK-Bio 1100 0.051 0.029 ± 0.02 0.15 0.053 ± 0.03

123

cells extravasated/section
log(fa/fu)

Breast Cancer Res Treat

A B
5000

MDA-MB-231
cN-MAP
PhScN

1000
800

SUM149PT

PHSCN

600
400
200
0

Con
10 100 1000
1 10 100
1 10 100

ng/ml PHSCN ng/ml PhScN pg/ml cN-MAP
log(ng/ml)

⦁ ontrol PhScN PHSCN

⦁

Fig. 3 Increased extravasation inhibition by Ac-PhScN-NH

or Ac-

sectioned lung tissue for MDA-MB231 extravasation analyzed by

PhScNGGK-MAP prebinding, relative to Ac-PHSCN-NH2 peptide.
confocal microscopy after pretreatment with 100 ng/ml Ac-PhScN-

a Y axes, average cells extravasated/section; X axes, Con, control; 10,
NH
2
or 100 ng/ml Ac-PHSCN-NH
2, compared to untreated control.

100, 1000 ng/ml PHSCN; 1, 10, 100 ng/ml PhScN; 1, 10, 100 pg/ml PhScNGGK-MAP. b Median-effect plot for extravasation into lung
d Typical examples of sectioned lung tissue for SUM149PT extravasation analyzed by confocal microscopy after pretreatment

after prebinding with PHSCN (circles), PhScN (squares ) or PhScN-
with 100 ng/ml Ac-PhScN-NH
2
or 1000 ng/ml Ac-PHSCN-NH
2,

MAP (triangles ); open symbols MDA-MB231 cells; closed symbols SUM 149 PT cells. X axes, log peptide concentration in ng/ml; Y axes,
compared to untreated control. Images represent the merged com- posite of DiI-labeled cells shown in orange; blue stained nuclei from

mean log fraction affected/fraction unaffected (f
a
/f
u) ± SEM. IC50
DAPI Mounting Medium; green tissue from actin staining. (Color

and DRI values are summarized in Table 3. c Typical examples of

those observed for metastatic prostate cancer [9]. Fig-
ﬁgure online)

by confocal microscopic analysis after pretreatment with

ure 3c, d shows typical examples of sectioned lung tissue
100 ng/ml Ac-PhScN-NH
2
or 100 ng/ml Ac-PHSCN-NH
2
,

for MDA-MB-231 and SUM149PT extravasation, obtained 123
versus untreated or scrambled sequence controls.

2 3
2 3
5
6

Breast Cancer Res Treat

Table 3 Extravasation Inhibition, IC50’s and DRI values for PhScN, PHSCN, and the PhScNGGK-dendrimer, cN-MAP
Mw SUM149PT MDA-MB-231 DRI

treated with hSPNc demonstrates that although elevated PhScN concentrations are required for activated Caspase-3 upregulation, the effect is sequence speciﬁc.

IC
50
IC50
PhScN exhibits a similar increase in lung colonization-

pg/ml pg/ml pg/ml M
inhibitory potency, relative to PHSCN, for MDA-MB-231

PHSCN 598 214 61 1
1
and SUM149PT (1000- to 10,000-fold). However, the

PhScN 598 2.0 0.036 10 –10
10 –10
corresponding IC
50
values are 10- to 100-fold higher for

cN-MAP 7500 0.0005 0.0006 10
10
6
SUM149PT (Table 4)—perhaps due to differences between metastatic and inﬂammatory cancer cell lines—

Increased potency of PhScN peptide as an inhibitor of lung colonization

Since extravasated cells may not establish a metastasis [23], effects of PhScN or PHSCN pretreatment on lung colonization were determined by allowing extravasated cells to grow 6 weeks without further treatment. Figure 4a shows the comparison of the effects of prebinding various concentrations of PhScN or PHSCN to suspended, DiI- labeled SUM149PT or MDA-MB-231 on lung colonization after tail vein injection. Dose response curves in Fig. 4b are
the DRI values suggest that PhScN is 1000- to 10,000-fold more potent at preventing lung colonization than PHSCN for both MDA-MB-231 and SUM149PT.

Inhibition of MDA-MB-231 bone metastasis progression by systemic PhScN

Breast cancer bone metastasis occurs earlier than lung colonization [3]. Interaction with surrounding bone marrow and matrix is described by the ‘‘vicious cycle’’model [2], in which parathyroid hormone-related protein (PTHrP) expressed by breast cancer cells after bone colonization [25], stimulates progression and enhances osteoclastic bone

median-effect plots, and the IC
50
and DRI values are
resorption [24, 26–28]. Metastatic breast cancer cell signals

summarized in Table 4. Both PhScN and PHSCN pre- treatment log-linearly decreased MDA-MB-231 and SUM149PT lung colonization. PhScN was 3850-fold more potent than PHSCN for reducing SUM149PT lung colony formation, and 32,143-fold more potent for MDA-MB-231. Furthermore, since all of the 120 control (untreated, Ac- HSPNC-NH2- or Ac-hSPNc-NH2-treated) mice, injected intravenously with suspended SUM149PT or MDA-MB- 231 cells, had to be euthanized to prevent suffering due to respiratory distress, while none of the PhScN-treated mice did, systemic PhScN therapy may also be a more potent inhibitor of respiratory distress due to lung metastasis progression. Figure 4c shows the examples of DiI-labeled MDA-MB-231 colonies in ﬂuorescent actin- and DAPI- stained lung tissue after no treatment, and after prebinding of the injected cells to 100 ng/ml of either PHSCN or PhScN. SUM149PT lung colonies had a similar appear- ance, data not shown.
Since stress activates a5b1 [24], and apoptosis induction could increase PhScN potency, we assessed apoptosis in vitro by examining effects of a 1-h treatment with a range of Ac-PhScN-NH2 concentrations. Figure 4d pre- sents a typical Western blot indicating that PhScN rapidly induces dose-dependent upregulation of activated Caspase- 3 in adherent SUM149PT. However, the concentrations are 1000- to 100,000-fold higher than those required for lung colonization inhibition. Lack of effect of an elevated con- centration of a scrambled sequence control, 500 lg Ac-
induce osteoblasts to express osteoclast stimulatory factors [29], stimulating multinucleated osteoclasts to resorb mineralized bone matrix [30–32] and release sequestered growth factors that interact with their receptors to promote metastatic growth by stimulating angiogenesis [33–36]. Activated a5b1 receptors of microvascular endothelial cells interact with the pFn PHSRN sequence to induce angiogenic invasion [6]. Matrix metalloproteinase-1 (MMP1), induced by a5b1 FnR binding to PHSRN, mediates both angiogenic and metastatic invasion by breast, prostate, and pancreatic cancer cells [4–6, 14]. MMP-1 activates the protease activated receptor-1 (PAR-1) gene in both breast cancer [37] and endothelial cells [38], thereby promoting breast cancer invasion and angiogene- sis. PTHrP stimulates osteoblasts to induce progenitor differentiation into active osteoclasts which mediate bone resorption, releasing epidermal growth factor (EGF)-like growth factors to further stimulate bone metastasis pro- gression [39]. Overexpression of receptor tyrosine-protein kinase erbB-2 (HER2) induces a5b1-mediated, mammary epithelial cell invasion [40], due to surface downregulation of the invasion-inhibitory a4b1 integrin [41]. Furthermore, MDA-MB-231 colonies in the bones of athymic mice can induce angiogenesis in osteolytic metastases [36]. Identi- ﬁcation of a5b1 as the primary integrin ﬁbronectin receptor on human bone marrow stroma [42] suggests that PhScN could be effective in reducing bone metastases. These interactions and the potential inhibitory effects of PhScN

hSPNc-NH
2
per 10 SUM149PT cells, is also shown. Lack
therapy on a5b1-mediated breast cancer (BC) and angio-

of activated Caspase-3 upregulation in SUM149PT cells
genic invasion are diagrammed in Scheme 1.

123

6
6
4
-13
-9

Breast Cancer Res Treat

Fig. 4 Increased inhibition of lung colonization by Ac-PhScN-NH

PHSCN-NH

compared to untreated control. Images represent the

prebinding, relative to Ac-PHSCN-NH2. a Y axes, average colonies/section; X axes, Con, control; NC, 100 ng/ml HSPNC or hSPNc; 10, 100, 1000 ng/ml PHSCN; 1, 10, 100 ng/ml PhScN. b Median-effect plot for lung colony formation after prebinding to PHSCN (circles) or PhScN (squares ). Closed symbols, dotted lines
merged composite of DiI-labeled cells shown in orange; blue stained nuclei from DAPI Mounting Medium; green tissue from actin staining. d Example of a typical Western blot showing dose- dependent upregulation of activated Caspase-3 in adherent SUM149PT cells by a 1-h treatment with a range of Ac-PhScN-

SUM149PT cells; open symbols, solid lines MDA-MB-231 cells.
NH
2
concentrations (10, 50, 100, 200, or 300 lg/10 cells). Micro-

X axes, log peptide concentration in ng/ml. Y axes, mean log fraction affected/fraction unaffected (fa/fu) ± SEM. IC50 and DRI values are summarized in Table 4. c Typical examples of sectioned lung tissue for MDA-MB-231 colonization analyzed by confocal microscopy
grams of Ac-PhScN-NH2 per million SUM149PT cells are indicated. Lack of effects of an elevated concentration of a scrambled sequence control, 500 lg Ac-hSPNc-NH2 per 10 SUM149PT cells, is also shown. (Color ﬁgure online)

after pretreatment with 100 ng/ml Ac-PhScN-NH
2
or 100 ng/ml Ac-

We evaluated microvascular endothelial cell (hmvec)
PhScN demonstrated a 6.3 9 10 -fold increase in potency

invasion in vitro as described [6]; PHSCN and PhScN were conﬁrmed to block invasion. The IC
values were similar
50
over PHSCN (PhScN IC
8.4 9 10 M).
50
, 1.3 9 10 M; PHSCN IC
50
,

to those determined for MDA-MB-231 and SUM149PT.

123

Scheme 1 Vicious cycle model of breast cancer bone metastasis. BC breast cancer, MMP-1 matrix metalloproteinase-1 interstitial colla- genase, PTHrP parathyroid hormone-related protein, EGF-like GFs epidermal growth factor-like growth factors, EGFR epidermal growth
3 4
3 4

Breast Cancer Res Treat

Table 4 Effects of PHSCN or PhScN pretreatment on lung colonization
SUM149PT MDA-MB-231 DRI

systemic treatments. As shown in Fig. 5a, 50 mg/kg sys- temic PhScN monotherapy reduced bone colony progres- sion by 77 %, compared to 57 % for 50 mg/kg PHSCN.

IC50 IC50
Median-effect analyses, Fig. 5b, indicate a dosage IC
50
of

pg/ml pg/ml pg/ml M
0.4 mg/kg for PhScN and 10 mg/kg for PHSCN. The DRI

PHSCN 4890 450 1 PhScN 1.27 0.014 10 –10
1
10 –10
values indicate that PhScN is 25-fold more potent than PHSCN as a systemic inhibitor of bone metastasis pro- gression. As seen in confocal microscopy examples, Fig. 5c, few cells remained in the bone marrow of 50 mg/ kg PhScN-treated mice; signiﬁcantly more were present in

To compare the effects of PHSCN and PhScN on established bone metastases, DiI-labeled, untreated MDA- MB-231 cells were injected intratibially and allowed to grow into intra-osteal colonies for 2 weeks before thrice- weekly systemic treatments of 5 or 50 mg/kg of PhScN or PHSCN were initiated. Systemic treatments were contin- ued for 24 days. Each mouse received a total of 10

factor receptor
marrows of mice treated with 50 mg/kg PHSCN. Bone colonies appeared to be either extravascular, or closely associated with the vasculature.

Colocalization of Ac-PhScNGGK-Bio with DiI
in extravasated breast cancer cells

Since nodal metastases occur in at least 20 % of patients undergoing completion axillary lymph node dissection (ALND) following a positive sentinel lymph node biopsy (SLNB), the use of SLNB alone for axilla staging under- estimates nodal disease [43]. Hence, a more efﬁcient means of detecting metastatic disease would be beneﬁcial. Ac- PhScNGGK-Bio might be an efﬁcient detection agent for extravasated breast cancer cells in sectioned biopsies. Thus, we assessed Ac-PhScNGGK-Bio/DiI colocalization in tail vein-injected, lung-extravasated SUM149PT cells. As shown in Fig. 6a, a range of Ac-PhScNGGK-Bio con- centrations (1.0–50.0 lg per ml) labeled 89–90 % of extravasated cells 24 h after injection, suggesting that labeled PhScN is efﬁcient agent for detecting extravasated breast cancer cells. Figure 6b shows representative images of extravasated DiI-labeled SUM149PT, with and without Ac-PhScNGGK-Bio.

Discussion

Since recurrent or metastatic disease develops in 40 % of early breast cancer patients [1], with bone metastasis in most [2], there is an urgent need for effective therapy to prevent metastatic and angiogenic invasion. As summa- rized in Scheme 1, inhibition of activated a5b1 receptors on metastatic breast cancer and associated microvascular endothelial cells may form the basis of an effective tar- geted therapy to inhibit the vicious cycle of bone metastasis progression. Because overexpression of PTHrP in MDA- MB-231 cells induces a 10- to 25-fold upregulation of a5 integrin expression and increased a5b1 integrin [44], and because a5b1 mediates metastatic invasion, systemic dis- semination [4, 5, 14, 16, 45], and microvascular endothelial cell invasion [6], a5b1 is a key therapeutic target [4–9, 14, 17].

123

5
8

Breast Cancer Res Treat

Fig. 5 Increased potency of PhScN as a systemic therapy to prevent breast cancer bone colony progression in athymic mice. a Anti- metastatic potencies of systemic PhScN (Ac-PhScN-NH 2) versus

fu) ± SEM. c Examples of bone marrow from untreated mice, and from mice treated with a total of 10 thrice-weekly tail vein injections of 50 mg/kg PhScN or 50 mg/kg PHSCN. Images represent the

PHSCN (Ac-PHSCN-NH
2) for reducing MDA-MB-231 bone marrow
merged composite of DiI-labeled cells shown in orange; stained

progression in athymic mice. Y axes, average colonies per section; X axes, Con, untreated control; 5 and 50 mg/kg PhScN; 5 and 50 mg/ kg PHSCN. b Median-effect plot for effects of PhScN versus PHSCN on bone marrow progression, X axis, log peptide dosage level (mg/ kg); Y axis, mean log fraction affected/fraction unaffected (fa/

Scheme 1 suggests that by targeting a5b1, PhScN may inhibit both angiogenesis and breast cancer bone invasion, as well as reducing bone resorption through its inhibitory effects on PTHrP- and growth factor-mediated signaling. We report that D-His, D-Cys-containing PhScN peptide is 10 -fold more potent than PHSCN as an inhibitor of a5b1- mediated, basement membrane invasion, 100- to 1000-fold more potent as an inhibitor of lung extravasation, and 3800- to 32,000-fold more potent at reducing lung colo- nization, when the effects of a single exposure to each peptide were compared. Since all untreated, HSPNC- or hSPNc-treated mice had to be euthanized to prevent suf- fering due to respiratory distress from the effects of SUM149PT or MDA-MB-231 overgrowth of their lungs, systemic PhScN therapy might also be able to reduce suffering due to lung metastasis progression in breast cancer patients.
Results were also presented showing that the multivalent presentation of PhScN sequence increases its relative potency on a molar basis by an additional 10 -fold as an

123
nuclei from DAPI Mounting Medium in blue; tissue from actin staining in green . Thus, DiI-labeled cells appear orange (Control) or green with orange inclusions (50 mg/kg PHSCN). No DiI-labeled cells appear in the image of sectioned bone from mice receiving 50 mg/kg PhScN. (Color ﬁgure online)

in vitro invasion inhibitor, or by an additional 1000- to 10,000-fold as a lung extravasation inhibitor. Consistent with the key role of a5b1-mediated invasion in metastatic progression [4–6], we also report that systemic PhScN monotherapy was well-tolerated and reduced bone colony progression. Our results also suggested that labeled PhScN is an efﬁcient agent for detecting extravasated, potentially metastatic breast cancer cells, due to surface-activated a5b1 integrin expression.
Advanced breast cancer patients are currently treated with Denosumab anti-receptor activator of nuclear factor kappa-B (RANK) ligand MAb or zoledronic acid to man- age the bone metastasis symptoms and delay skeletal related events (SRE). However, neither treatment delays disease progression or increases overall survival [46–48]. In contrast, PhScN monotherapy demonstrated a nearly 80 % reduction of bone colony progression on established intra-osteal colonies. Thus, by targeting a5b1 receptors PhScN may offer the opportunity to slow disease pro- gression and break the vicious cycle.

Breast Cancer Res Treat

Acknowledgments The authors wish to thank Steve Kronenberg in the Department of Radiation Oncology, University of Michigan for drawing the bone metastasis model depicted in Scheme 1. We also wish to thank the University of Michigan Ofﬁce of Technology Transfer for their work on patent 8,940,701: Compounds for, and methods of treating cancer and inhibiting invasion and metastases. The in vitro studies and lung metastasis research described here were supported by a Department of Defense Idea Expansion Award F028579. The bone metastasis research described here was supported by a grant from the Michigan Economic Development Corporation, through the University of Michigan Medical School’s Strategic Research Initiative, U-M MTRAC for Life Sciences.

Authors’contributions Hongren Yao performed all of the tissue preparations and confocal microscopic studies necessary for the analysis of the effects of PhScN on lung extravasation and lung colonization. He also performed all of the intratibial injections and tissue preparations, as well as all of the confocal microscopic analysis

of bone marrow progression. Donna Veine performed all of the K
d

Fig. 6 Colocalization of Ac-PhScNGGK-Bio with DiI in lung- extravasated SUM149PT cells. a Percentage of DiI-labeled cells in lung tissue binding to different concentrations of Ac-PhScNGGK- Bio: 1, 5, or 50 lgper ml. X axis, binding agents: hSPNc, Ac-hSPNc- NH2 (a scrambled sequence control peptide); PhScN, Ac- PhScNGGK-Bio. Y axis, mean percentage of biotinylated, DiI-labeled SUM149PT cells (±SEM). b Examples of ﬂuorescently stained lung tissue: control, no PhScNGGK-Bio; 50 lg PhScNGGK-Bio, 50 lg per ml Ac-PhScNGGK-Bio. DiI-labeled cells shown in orange; stained nuclei from DAPI Mounting Medium in blue; tissue from actin staining in green . (Color ﬁgure online)
determinations, competition binding assays, in vitro invasion assay preparations, data analysis, ﬁgure preparation and assisted in manu- script writing. Donna Livant performed all of the in vitro invasion assay data collections, as well as planning and directing the project, and writing the manuscript.

Compliance with ethical standards

Conﬂict of interest The author, Donna Livant, received salary from the University of Michigan, which owns the patent on her invention, patent 8,940,701: Compounds for, and methods of treating cancer and inhibiting invasion and metastases. The authors, Hongren Yao and Donna Veine declare that they have no competing interests.

References

⦁ Dickson RB, Lippman ME (2001) Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles & practice of oncology, 6th edn. Lippencott Williams & Wilkins, Philadelphia, pp 1633–1726
⦁ Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584 –593. doi:⦁ 10.⦁ ⦁ 1038/nrc867
⦁ Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Bur- ghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58 –68. doi:⦁ 10.1016/j.ccr.2007.12.003⦁
⦁ Jia Y, Zeng ZZ, Markwart SM, Rockwood KF, Ignatoski KM, Ethier SP, Livant DL (2004) Integrin ﬁbronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res 64(23):8674–8681. doi:⦁ 10.1158/0008-5472.CAN-04-0069
⦁ Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S (2000) Upadhyaya A anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 60(2):309–320
⦁ Zeng Z-Z, Yao H, Staszewski ED, Rockwood KF, Markwart SM, Fay KS, Spalding AC, Livant DL (2009) (alpha)5(beta)1 integrin ligand PHSRN induces invasion and (alpha)5 mRNA in endothelial cells to stimulate angiogenesis. Transl Oncol 2:8–20
⦁ Yao H, Veine D, Fay K, Staszewski E, Zeng Z-Z, Livant D (2011) The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation. Breast Cancer Res Treat 125:363–375

123

⦁ Yao H, Veine DM, Zeng ZZ, Fay KS, Staszewski ED, Livant DL (2010) Increased potency of the PHSCN dendrimer as an inhi- bitor of human prostate cancer cell invasion, extravasation, and lung colony formation. Clin Exp Metastasis 27(3):173–184. doi:⦁ 10.1007/s10585-010-9316-1
⦁ Veine DM, Yao H, Stafford DR, Fay KS, Livant DL (2014) A D-amino acid containing peptide as a potent, noncovalent inhi- bitor of alpha5beta1 integrin in human prostate cancer invasion and lung colonization. Clin Exp Metastasis 31:379–393. doi:⦁ 10.⦁ ⦁ 1007/s10585-013-9634-1
⦁ Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel- Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP (2008) Pharmacology of the novel antiangiogenic peptide ATN- 161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 14:2137–2144
⦁ van Golen KL, Bao L, Brewer GJ, Pienta KJ, Kamradt JM, Livant DL, Merajver SD (2002) Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carci- noma. Neoplasia 4(5):373–379. doi:⦁ 10.1038/sj.neo.7900258⦁
⦁ Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Donate F, Shaw DE, Mazar AP, Rabbani SA (2006) A non- RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Can Ther 5:2271–2280
⦁ Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM (2003) Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 104:496–503
⦁ Yao H, Zeng Z-Z, Fay KS, Veine DM, Straszewski ED, Morgan MA, Wilder-Romans K, Williams TM, Spalding AC, Ben-Josef E, Livant DL (2011) Role of alpha5beta1 integrin upregulation in radiation-induced invasion by human pancreatic cancer cells. Transl Oncol 4(5):282 –292
⦁ Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB (2006) Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antago- nist, in patients with solid tumours. Br J Cancer 94(11):1621–1626. doi:⦁ 10.1038/sj.bjc.6603171⦁
⦁ Zeng Z-Z, Jia YF, Hahn NJ, Markwart SM, Rockwood KF, Livant DL (2006) Role of focal adhesion kinase and phos- phatidylinositol 3 -kinase in integrin ﬁbronectin receptor- mediated, matrix metalloproteinase-1 dependent invasion by metastatic prostate cancer cells. Cancer Res 66(16):8091 – 8099
⦁ Livant DL, Brabec RK, Kurachi K, Allen DL, Wu Y, Andrews P, Ethier SP, Markwart S (2000) The PHSRN sequence induces extracellular matrix invasion and accelerates wound healing in obese diabetic mice. J Clin Invest 105(11):1537–1545
⦁ Hulme EC (1992) Centrifugation binding assays. In: Hulme EC (ed) Receptor–ligand interactions: a practical approach. Oxford University Press, Oxford, pp 235–246
⦁ Motulsky HJ, Neubig RR. Analyzing binding data. Current pro- tocols in neuroscience/editorial board, Jacqueline N Crawley [et al] 2010; Chapter 7:Unit 7 5. doi:⦁ 10.1002/0471142301.⦁ ⦁ ns0705s52⦁
⦁ Hall CL, Dai J, van Golen KL, Keller ET, Long MW (2006) Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66(17):8648–8654. doi:⦁ 10.1158/0008-5472.CAN-06-1544
⦁ Chou TC, Talalay P (1984) Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

123
Breast Cancer Res Treat

⦁ Aota S, Nomizu M, Yamada KM (1994) The short amino acid sequence Pro-His-Ser-Arg-Asn in human ﬁbronectin enhances cell-adhesive function. J Biol Chem 269(40):24756 –24761
⦁ Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695. doi:⦁ 10.1016/j.cell.2006.11.001
⦁ Jean C, Gravelle P, Fournie JJ, Laurent G (2011) Inﬂuence of stress on extracellular matrix and integrin biology. Oncogene 30(24):2697–2706. doi:⦁ 10.1038/onc.2011.27⦁
⦁ Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY et al (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237(4817):893 –896
⦁ Alonso V, de Gortazar AR, Ardura JA, Andrade-Zapata I, Alvarez-Arroyo MV, Esbrit P (2008) Parathyroid hormone-re- lated protein (107–139) increases human osteoblastic cell sur- vival by activation of vascular endothelial growth factor receptor- 2. J Cell Physiol 217(3):717–727. doi:⦁ 10.1002/jcp.21547⦁
⦁ Esbrit P, Alvarez-Arroyo MV, De Miguel F, Martin O, Martinez ME, Caramelo C (2000) C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11(6):1085–1092
⦁ Isowa S, Shimo T, Ibaragi S, Kurio N, Okui T, Matsubara K, Hassan NM, Kishimoto K, Sasaki A (2010) PTHrP regulates angiogenesis and bone resorption via VEGF expression. Anti- cancer Res 30(7):2755–2767
⦁ Guise TA (1997) Parathyroid hormone-related protein and bone metastases. Cancer 80(8 Suppl):1572–1580
⦁ Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastoge- nesis, lymphocyte development and lymph-node organogenesis. Nature 397(6717):315 –323. doi:⦁ 10.1038/16852⦁
⦁ Blair HC, Teitelbaum SL, Ghiselli R, Gluck S (1989) Osteo- clastic bone resorption by a polarized vacuolar proton pump. Science 245(4920):855 –857
⦁ Delaisse JM, Engsig MT, Everts V, del Carmen Ovejero M, Ferreras M, Lund L, Vu TH, Werb Z, Winding B, Lochter A, Karsdal MA, Troen T, Kirkegaard T, Lenhard T, Heegaard AM, Neff L, Baron R, Foged NT (2000) Proteinases in bone resorp- tion: obvious and less obvious roles. Clin Chim Acta 291(2):223–234
⦁ Tang X, Zhang Q, Shi S, Yen Y, Li X, Zhang Y, Zhou K, Le AD (2010) Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 126(1):90–103. doi:⦁ 10.1002/ijc.24710⦁
⦁ Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ (1995) T lymphocytes that inﬁltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic ﬁbroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA 92(14):6547–6551
⦁ Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G, Ten Dijke P (2010) Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene 29(9):1351–1361. doi:⦁ 10.1038/onc.2009.426⦁
⦁ Winding B, Misander H, Sveigaard C, Therkildsen B, Jakobsen M, Overgaard T, Oursler MJ, Foged NT (2000) Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis. J Cancer Res Clin Oncol 126(11):631–640
⦁ Boire A, Covic L, Agarwal A, Jacques S, Sheriﬁ S, Kuliopulos A (2005) PAR1 is a matrix metalloprotease-1 receptor that

Breast Cancer Res Treat

promotes invasion and tumorigenesis of breast cancer cells. Cell 120(3):303–313. doi:10.1016/j.cell.2004.12.018
⦁ Blackburn JS, Brinckerhoff CE (2008) Matrix metalloproteinase- 1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol 173(6):1736–1746. doi:⦁ 10.2353/ajpath.2008.080512⦁
⦁ Foley J, Nickerson N, Riese DJ 2nd, Hollenhorst PC, Lorch G, Foley AM (2012) At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology 100(2):109–129. doi:⦁ 10.1007/s10266-012-0070-5
⦁ Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL,

⦁ Korah R, Boots M, Wieder R (2004) Integrin alpha5beta1 pro- motes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 64(13):4514–4522. doi:⦁ 10.1158/0008-5472.CAN-03-⦁ ⦁ 385364/13/4514
⦁ Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. doi:⦁ 10.1200/JCO.2010.⦁

Ethier SP (2000) ERBB-2 overexpression confers PI 3
0
kinase-
29.7101

dependent invasion capacity on human mammary epithelial cells. Br J Cancer 82(3):666–674. doi:10.1054/bjoc.1999.0979
⦁ Woods Ignatoski KM, Grewal NK, Markwart S, Livant DL, Ethier SP (2003) p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion. Neoplasia 5(2):128 –134
⦁ Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, De Weger RA, Van den Tweel JG, Joling P (1997) Fibro- nectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res 230(1):111–120. doi:⦁ 10.1006/excr.1996.3405
⦁ Noguchi M, Morioka E, Ohno Y, Noguchi M, Nakano Y, Kosaka T (2013) The changing role of axillary lymph node dissection for breast cancer. Breast Cancer 20(1):41–46. doi:⦁ 10.1007/s12282-⦁ ⦁ 012-0416-4⦁
⦁ Anderson JA, Grabowska AM, Watson SA (2007) PTHrP increases transcriptional activity of the integrin subunit alpha5. Br J Cancer 96(9):1394–1403. doi:⦁ 10.1038/sj.bjc.6603720⦁
⦁ Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-re- sistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822. doi: ⦁ 10.1016/S0140-6736(10)623⦁ ⦁ 44-6⦁
⦁ Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125–1132. doi:⦁ 10.1200/JCO.2010.31.3304

123